Program
Fluticasone
Also written as “Fluticasone Propionate”, “Fluticasone propionate” and “Fluticasone Propionate/Formoterol Fumarate”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Rhinitis, Allergic, Perennial, led by 24 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 580 open or running | phase 4since Feb 1, 2005 | Feb 1, 2005 | none ahead |
| Respirent Pharmaceuticals | 182 open or running | phase 3since Sep 17, 2018 | Sep 17, 2018 | none ahead |
| Teva Pharmaceutical Industries | 140 open or running | phase 4since Dec 11, 2020 | Nov 22, 2011 | none ahead |
| Viatris | 130 open or running | phase 4since Dec 16, 2016 | Nov 21, 2006 | none ahead |
| Optinose US | 101 open or running | phase 3since Jun 13, 2012 | Jun 13, 2012 | Mar 31, 2028phase 3 · NCT06850805 |
| Mundipharma | 60 open or running | phase 4since Jun 15, 2015 | Oct 14, 2009 | none ahead |
| SkyePharma | 50 open or running | phase 3since Oct 27, 2006 | Oct 27, 2006 | none ahead |
| Eurofarma Laboratorios | 31 open or running | phase 3since Sep 14, 2010 | Sep 14, 2010 | Aug 2028phase 3 · NCT06234345 |
| Merck | 30 open or running | phase 2since Oct 5, 2006 | Oct 5, 2006 | none ahead |
| Hikma Pharmaceuticals | 20 open or running | no phasesince Jan 5, 2016 | Jan 5, 2016 | none ahead |
| intech-biopharm-ltd | 20 open or running | phase 1since Jun 2, 2015 | Jun 2, 2015 | none ahead |
| nicox-ophthalmics-inc | 20 open or running | phase 2since Apr 19, 2019 | Apr 19, 2019 | none ahead |
| Organon | 20 open or running | phase 4since Oct 30, 2008 | Oct 30, 2008 | none ahead |
| Pfizer | 20 open or running | phase 1since Sep 21, 2009 | Sep 21, 2009 | none ahead |
| cipla-ltd | 10 open or running | phase 3since Dec 26, 2017 | Dec 26, 2017 | none ahead |
| fougera-pharmaceuticals-inc | 10 open or running | phase 4since Oct 16, 2007 | Oct 16, 2007 | none ahead |
| glenmark-pharmaceuticals-ltd-india | 10 open or running | phase 3since May 2, 2022 | May 2, 2022 | none ahead |
| HALEON | 11 open or running | phase 4since Aug 31, 2026 | Aug 31, 2026 | Dec 2026phase 4 · NCT07817134 |
| kindeva-drug-delivery | 10 open or running | phase 1since Sep 2, 2014 | Sep 2, 2014 | none ahead |
| libbs-farmace-utica-ltda | 10 open or running | phase 3since Apr 1, 2020 | Apr 1, 2020 | none ahead |
| Mannkind | 10 open or running | phase 1since May 5, 2008 | May 5, 2008 | none ahead |
| neothetics-inc | 10 open or running | phase 2since Oct 16, 2012 | Oct 16, 2012 | none ahead |
| ORA | 10 open or running | phase 4since Sep 19, 2011 | Sep 19, 2011 | none ahead |
| Orion Corporation, Orion Pharma | 10 open or running | phase 1since Mar 21, 2012 | Mar 21, 2012 | none ahead |
Also a collaborator on its studies: paratek-pharmaceuticals-inc, becro-ltd, prolytic-gmbh, dynamic-solutions, parexel, vectura-limited and ppd-development-lp.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Feb 15, 2013.
- Dec 7, 2020Phase 3 study in AsthmaRespirent Pharmaceuticals · NCT04665895 · 451 enrolled · Greece
- Dec 11, 2020Phase 4 study in AsthmaTeva Pharmaceutical Industries · NCT04677959 · 427 enrolled · United States
- Dec 15, 2020Phase 2 study in Blepharitisnicox-ophthalmics-inc · NCT04675242 · 224 enrolled · United States
- Feb 8, 2021Phase 1 study in AsthmaRespirent Pharmaceuticals · NCT04746040 · 50 enrolled · Greece
- Aug 19, 2021Phase 1 study in AsthmaRespirent Pharmaceuticals · NCT05021887 · 50 enrolled · Greece
- Oct 8, 2021Phase 1 study in AsthmaRespirent Pharmaceuticals · NCT05085587 · 18 enrolled · Greece
- May 2, 2022glenmark-pharmaceuticals-ltd-india's first study: phase 3 study in AsthmaNew to glenmark-pharmaceuticals-ltd-indiaglenmark-pharmaceuticals-ltd-india · NCT05363202 · 790 enrolled · India
- May 25, 2022Phase 1 study in AsthmaRespirent Pharmaceuticals · NCT05397834 · 36 enrolled · Greece
- Dec 15, 2022Phase 3 study in AsthmaRespirent Pharmaceuticals · NCT05664061 · 451 enrolled · Greece
- Jan 10, 2023Phase 1 study in BioequivalenceRespirent Pharmaceuticals · NCT05697003 · 34 enrolled · Greece
- Aug 1, 20232 phase 1 studies in BioequivalenceRespirent Pharmaceuticals · NCT05982990, NCT06025214
- Jan 3, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveEurofarma Laboratorios · NCT06234345 · 1,252 planned · Brazil
- Feb 14, 2025Phase 3 study in Chronic Rhinosinusitis Without Nasal PolypsOptinose US · NCT06850805 · 84 planned · United States
- Aug 31, 2026HALEON's first study: phase 4 study in Rhinitis, Allergic, PerennialNew to HALEONHALEON · NCT07817134 · 16 planned · Canada
Ahead
- Dec 2026Primary completion: phase 4 study in Rhinitis, Allergic, PerennialHALEON · NCT07817134
- Mar 31, 2028Primary completion: phase 3 study in Chronic Rhinosinusitis Without Nasal PolypsOptinose US · NCT06850805
- Aug 2028Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveEurofarma Laboratorios · NCT06234345
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The newest 60 of 150 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07817134Rhinitis, Allergic, Perennial · Canada | 4 | Not yet recruiting | HALEON | Dec 2026 | 16 |
| NCT06850805Chronic Rhinosinusitis Without Nasal Polyps · United States | 3 | Recruiting | Optinose US | Mar 31, 2028 | 84 |
| NCT06234345Pulmonary Disease, Chronic Obstructive · Brazil | 3 | Not yet recruiting | Eurofarma Laboratorios | Aug 2028 | 1,252 |
| NCT06025214Bioequivalence · Greece | 1 | Recruiting | Respirent Pharmaceuticals | Sep 22, 2023 | 34 |
| NCT05982990Bioequivalence · Greece | 1 | Active, not recruiting | Respirent Pharmaceuticals | Sep 1, 2023 | 34 |
| NCT05697003Bioequivalence · Greece | 1 | UNKNOWN | Respirent Pharmaceuticals | Mar 31, 2023 | 34 |
| NCT05664061Asthma · Greece | 3 | UNKNOWN | Respirent Pharmaceuticals | Jul 31, 2023 | 451 |
| NCT05397834Asthma · Greece | 1 | UNKNOWN | Respirent Pharmaceuticals | Jun 21, 2022 | 36 |
| NCT05363202Asthma · India | 3 | UNKNOWN | glenmark-pharmaceuticals-ltd-india | May 30, 2024 | 790 |
| NCT05085587Asthma · Greece | 1 | UNKNOWN | Respirent Pharmaceuticals | Oct 25, 2021 | 18 |
| NCT05021887Asthma · Greece | 1 | UNKNOWN | Respirent Pharmaceuticals | Sep 30, 2021 | 50 |
| NCT04746040Asthma · Greece | 1 | UNKNOWN | Respirent Pharmaceuticals | Feb 25, 2021 | 50 |
| NCT04675242Blepharitis · United States | 2 | Completed | nicox-ophthalmics-inc | Jun 16, 2021 | 224 |
| NCT04677959Asthma · United States | 4 | Completed | Teva Pharmaceutical Industries | Mar 4, 2022 | 427 |
| NCT04665895Asthma · Greece | 3 | Completed | Respirent Pharmaceuticals | Aug 13, 2021 | 451 |
| NCT04564456Bioequivalence · Greece | 1 | Completed | Respirent Pharmaceuticals | Oct 31, 2020 | 34 |
| NCT04546256Bioequivalence · Greece | 1 | Completed | Respirent Pharmaceuticals | Sep 25, 2020 | 14 |
| NCT04466176Bioequivalence · Greece | 1 | Completed | Respirent Pharmaceuticals | Aug 4, 2020 | 34 |
| NCT04462822Bioequivalence · Greece | 1 | Completed | Respirent Pharmaceuticals | Sep 9, 2020 | 14 |
| NCT04332978Rhinitis, Allergic, Perennial | 3 | Completed | libbs-farmace-utica-ltda | Apr 1, 2020 | 566 |
| NCT04271839Persistent Asthma | 4 | Withdrawn | Mundipharma | May 2021 | 0 |
| NCT03975166Bioequivalence · Greece | 1 | Completed | Respirent Pharmaceuticals | Jun 25, 2019 | 34 |
| NCT03960580Chronic Rhinosinusitis · United States, Australia, Bulgaria and more | 3 | Completed | Optinose US | May 4, 2022 | 223 |
| NCT03926026Blepharitis · United States | 2 | Completed | nicox-ophthalmics-inc | Oct 21, 2019 | 36 |
| NCT03894280Bioequivalence · Greece | 1 | Completed | Respirent Pharmaceuticals | Apr 9, 2019 | 36 |
| NCT03820180Bioequivalence · Greece | 1 | Completed | Respirent Pharmaceuticals | Feb 12, 2019 | 34 |
| NCT03781804Chronic Rhinosinusitis · United States, Bulgaria, Canada and more | 3 | Completed | Optinose US | Jan 19, 2022 | 332 |
| NCT03756883Asthma · United States | 3 | Completed | Teva Pharmaceutical Industries | Oct 26, 2019 | 999 |
| NCT03751202Bioequivalence · Greece | 1 | Completed | Respirent Pharmaceuticals | Dec 11, 2018 | 34 |
| NCT03747458Bilateral Nasal Polyposis · United States, Argentina | 3 | Completed | Optinose US | Mar 31, 2026 | 40 |
| NCT03676413Asthma · Greece | 3 | Completed | Respirent Pharmaceuticals | Aug 2, 2019 | 451 |
| NCT03591068Nasal Polyps · United States | 3 | Completed | Optinose US | Feb 22, 2019 | 11 |
| NCT03535870Asthma · United States | – | Completed | Hikma Pharmaceuticals | Sep 10, 2019 | 1,556 |
| NCT03394989Asthma · United States | 3 | Completed | cipla-ltd | Dec 3, 2019 | 1,366 |
| NCT03387241Asthma · China | 3 | UNKNOWN | Mundipharma | Dec 30, 2019 | 330 |
| NCT03004131Rhinitis, Allergic, Seasonal · Canada | 4 | Completed | Viatris | Mar 29, 2017 | 82 |
| NCT02980133Asthma · United States, Georgia, Hungary and more | 3 | Completed | Teva Pharmaceutical Industries | Apr 7, 2019 | 841 |
| NCT02730351Asthma · United States, Canada | 4 | Completed | GlaxoSmithKline | Feb 3, 2017 | 75 |
| NCT02680561Asthma · United States | 1 | Completed | Teva Pharmaceutical Industries | Jun 2016 | 20 |
| NCT02693769ACOS (Fixed Airflow Obstruction and Elevated Eosinophils) · Slovakia | 3 | Terminated | Mundipharma | Oct 2016 | 2 |
| NCT02649478Asthma · United States | – | Completed | Hikma Pharmaceuticals | Nov 2015 | 1,430 |
| NCT02496715Asthma | 3 | Withdrawn | Teva Pharmaceutical Industries | Oct 2016 | 0 |
| NCT02491970Asthma | 4 | Terminated | Mundipharma | Apr 6, 2017 | 15 |
| NCT02466503Asthma · Taiwan | 1 | Completed | intech-biopharm-ltd | Sep 2014 | 45 |
| NCT02466347Asthma · Taiwan | 1 | Completed | intech-biopharm-ltd | Aug 2014 | 45 |
| NCT02437604Asthma · United States | 1 | Completed | Teva Pharmaceutical Industries | Jul 2015 | 43 |
| NCT02301975Asthma · United States, Argentina, Brazil and more | 3 | Completed | GlaxoSmithKline | Nov 1, 2016 | 1,526 |
| NCT02266927Mild to Moderate Asthma · Ireland | 1 | Completed | Optinose US | Mar 2015 | 28 |
| NCT02249663Rhinitis, Allergic, Seasonal · United States | 3 | UNKNOWN | Teva Pharmaceutical Industries | Feb 2015 | 1,535 |
| NCT02246920Rhinitis, Allergic, Seasonal · United States | 3 | Terminated | Teva Pharmaceutical Industries | Jul 14, 2014 | 1,474 |
| NCT02232087Healthy · United Kingdom | 1 | Completed | kindeva-drug-delivery | Oct 2014 | 52 |
| NCT02215122Asthma · United States | 1 | Completed | Viatris | Nov 2013 | 40 |
| NCT02175771Persistent Asthma · United States | 3 | Completed | Teva Pharmaceutical Industries | Jul 2015 | 758 |
| NCT02141854Asthma · United States, Canada, Czechia and more | 3 | Completed | Teva Pharmaceutical Industries | Sep 2015 | 882 |
| NCT02139644Asthma · United States, Canada, Czechia and more | 3 | Completed | Teva Pharmaceutical Industries | Sep 2015 | 787 |
| NCT02094937Asthma · Japan | 3 | Completed | GlaxoSmithKline | Aug 28, 2015 | 430 |
| NCT01915823Rhinitis, Allergic, Seasonal · United States | 3 | Completed | Viatris | Feb 2014 | 348 |
| NCT01915914Skin Diseases · China | 4 | Completed | GlaxoSmithKline | Feb 15, 2015 | 107 |
| NCT01817790Rhinitis, Allergic · United States | 3 | Completed | GlaxoSmithKline | Feb 2013 | 626 |
| NCT01794741Rhinitis, Allergic · United States | 3 | Completed | Viatris | Nov 2013 | 405 |
How it is read
Names in the registry
- “Fluticasone Propionate”, 17 entries
- “Fluticasone propionate”, 13 entries
- “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
- “fluticasone propionate”, 7 entries
- “fluticasone propionate/salmeterol”, 7 entries
Codes read as this program: NCX4251, FP100.
Conditions, from the studies’ own filings
- Asthma, 84 studies
- Pulmonary Disease, Chronic Obstructive, 18 studies
- Rhinitis, Allergic, Seasonal, 11 studies
- Rhinitis, Allergic, 9 studies
- Rhinitis, Allergic, Perennial, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.